

## Documents

Razali, K.<sup>a</sup>, Mohd Nasir, M.H.<sup>b</sup>, Kumar, J.<sup>c</sup>, Mohamed, W.M.Y.<sup>a d</sup>

**Mitophagy: A Bridge Linking HMGB1 and Parkinson's Disease Using Adult Zebrafish as a Model Organism**  
(2023) *Brain Sciences*, 13 (7), art. no. 1076, .

DOI: 10.3390/brainsci13071076

<sup>a</sup> Department of Basic Medical Sciences, Kulliyah of Medicine, International Islamic University Malaysia (IIUM), Pahang, Kuantan, 25200, Malaysia

<sup>b</sup> Department of Biotechnology, Kulliyah of Science, International Islamic University Malaysia (IIUM), Pahang, Kuantan, 25200, Malaysia

<sup>c</sup> Department of Physiology, Faculty of Medicine, UKM Medical Centre, Selangor, Kuala Lumpur, 56000, Malaysia

<sup>d</sup> Clinical Pharmacology Department, Menoufia Medical School, Menoufia University, Menoufia, Shebin El-Kom, 32511, Egypt

### Abstract

High-mobility group box 1 (HMGB1) has been implicated as a key player in two critical factors of Parkinson's disease (PD): mitochondrial dysfunction and neuroinflammation. However, the specific role of HMGB1 in PD remains elusive. We investigated the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration on mitochondrial dysfunction and HMGB1-associated inflammatory genes as well as locomotor activity in zebrafish, aiming to elucidate the role of HMGB1 in PD. Adult zebrafish received MPTP injections, and locomotor activity was measured at 24- and 48-h post-administration. Gene expression levels related to mitophagy (*fis1*, *pink1*, and *park2*) and HMGB1-mediated inflammation (*hmgb1*, *tlr4*, and *nfb*) were quantified through RT-qPCR analysis. Following MPTP injection, the significant increase in transcript levels of *fis1*, *pink1*, and *park2* indicated notable changes in PINK1/Parkin mitophagy, while the upregulation of *hmgb1*, *tlr4*, and *nfb* genes pointed to the activation of the HMGB1/TLR4/NFκB inflammatory pathway. Furthermore, MPTP-injected zebrafish exhibited decreased locomotor activity, evident through reduced distance travelled, mean speed, and increased freezing durations. HMGB1 plays a major role in cellular processes as it is involved in both the mitophagy process and functions as a pro-inflammatory protein. MPTP administration in adult zebrafish activated mitophagy and inflammatory signaling, highlighting the significant role of HMGB1 as a mediator in both processes and further emphasizing its significant contribution to PD pathogenesis. © 2023 by the authors.

### Author Keywords

high-mobility group box 1; mitochondrial dysfunction; MPTP; neuroinflammation; Parkinson's disease; zebrafish

### Index Keywords

1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine, high mobility group B1 protein, immunoglobulin enhancer binding protein, neurotoxin, toll like receptor 4, transcription factor Nrf2; animal experiment, animal model, animal tissue, apoptosis, Article, brain tissue, cell function, damage-associated molecular pattern-triggered immunity, disability, freezing, gene expression, gene expression level, genetic transcription, histology, locomotion, Locomotor impairment, long term potentiation, mitophagy, nerve degeneration, neurotoxicity, nonhuman, Parkinson disease, protein expression, protein function, real time polymerase chain reaction, respiratory chain, signal transduction, transcription initiation

### Chemicals/CAS

1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine, 28289-54-5; neurotoxin, 39386-17-9; toll like receptor 4, 203811-83-0

### References

- Hirsch, E.C., Standaert, D.G.  
**Ten unsolved questions about neuroinflammation in Parkinson's disease**  
(2021) *Mov. Disord*, 36, pp. 16-24.
- Blauwendraat, C., Nalls, M.A., Singleton, A.B.  
**The genetic architecture of Parkinson's disease**  
(2020) *Lancet Neurol*, 19, pp. 170-178.
- De Miranda, B.R., Goldman, S.M., Miller, G.W., Greenamyre, J.T., Dorsey, E.  
**Preventing Parkinson's disease: An environmental agenda**  
(2022) *J. Park. Dis*, 12, pp. 45-68.

- Tolosa, E., Garrido, A., Scholz, S.W., Poewe, W.  
**Challenges in the diagnosis of Parkinson's disease**  
(2021) *Lancet Neurol*, 20, pp. 385-397.
- Peplow, P.V., Martinez, B., Gennarelli, T.A.  
(2022) *Neurodegenerative Diseases Biomarkers: Towards Translating Research to Clinical Practice*,  
Springer, Berlin/Heidelberg, Germany
- Trifonova, O.P., Maslov, D.L., Balashova, E.E., Urazgildeeva, G.R., Abaimov, D.A., Fedotova, E.Y., Poleschuk, V.V., Lokhov, P.G.  
**Parkinson's disease: Available clinical and promising omics tests for diagnostics, disease risk assessment, and pharmacotherapy personalization**  
(2020) *Diagnostics*, 10, p. 339.
- Moon, H.E., Paek, S.H.  
**Mitochondrial dysfunction in Parkinson's disease**  
(2015) *Exp. Neurol*, 24, p. 103.
- Park, J.-S., Davis, R.L., Sue, C.M.  
**Mitochondrial dysfunction in Parkinson's disease: New mechanistic insights and therapeutic perspectives**  
(2018) *Curr. Neurol. Neurosci. Rep*, 18, p. 21.
- Belloli, S., Morari, M., Murtaç, V., Valtorta, S., Moresco, R.M., Gilardi, M.C.  
**Translation imaging in Parkinson's disease: Focus on neuroinflammation**  
(2020) *Front. Aging Neurosci*, 12, p. 152.
- Pajares, M., Rojo, A.I., Manda, G., Boscá, L., Cuadrado, A.  
**Inflammation in Parkinson's disease: Mechanisms and therapeutic implications**  
(2020) *Cells*, 9.
- Mani, S., Sevanan, M., Krishnamoorthy, A., Sekar, S.  
**A systematic review of molecular approaches that link mitochondrial dysfunction and neuroinflammation in Parkinson's disease**  
(2021) *Neurol. Sci*, 42, pp. 4459-4469.
- Ihenacho, U.K., Meacham, K.A., Harwig, M.C., Widlansky, M.E., Hill, R.B.  
**Mitochondrial fission protein 1: Emerging roles in organellar form and function in health and disease**  
(2021) *Front. Endocrinol*, 12, p. 660095.  
33841340
- Ge, P., Dawson, V.L., Dawson, T.M.  
**PINK1 and Parkin mitochondrial quality control: A source of regional vulnerability in Parkinson's disease**  
(2020) *Mol. Neurodegener*, 15, p. 20.
- Liu, S., Sawada, T., Lee, S., Yu, W., Silverio, G., Alapatt, P., Millan, I., Kanoo, T.  
**Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria**  
(2012) *PLoS Genet*, 8.
- Losón, O.C., Song, Z., Chen, H., Chan, D.C.  
**Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission**  
(2013) *Mol. Biol. Cell*, 24, pp. 659-667.
- Ganesan, S., Parvathi, V.D.  
**Deconstructing the molecular genetics behind the PINK1/Parkin axis in Parkinson's disease using *Drosophila melanogaster* as a model organism**  
(2021) *Egypt. J. Med. Hum. Genet*, 22, p. 86.

- Sun, Z., Ye, J., Yuan, J.  
**PINK1 mediates neuronal survival in monkey**  
(2022) *Protein Cell*, 13, pp. 4-5.
- Portz, P., Lee, M.K.  
**Changes in Drp1 function and mitochondrial morphology are associated with the  $\alpha$ -synuclein pathology in a transgenic mouse model of Parkinson's disease**  
(2021) *Cells*, 10.
- Qi, L., Sun, X., Li, F.-E., Zhu, B.-S., Braun, F.K., Liu, Z.-Q., Tang, J.-L., Wang, H.-H.  
**HMGB1 promotes mitochondrial dysfunction–triggered striatal neurodegeneration via autophagy and apoptosis activation**  
(2015) *PLoS ONE*, 10.
- Tang, D., Kang, R., Livesey, K.M., Kroemer, G., Billiar, T.R., Van Houten, B., Zeh, H.J., Lotze, M.T.  
**High-mobility group box 1 is essential for mitochondrial quality control**  
(2011) *Cell Metab*, 13, pp. 701-711.  
21641551
- Picca, A., Calvani, R., Coelho-Junior, H.J., Landi, F., Bernabei, R., Marzetti, E.  
**Mitochondrial dysfunction, oxidative stress, and neuroinflammation: Intertwined roads to neurodegeneration**  
(2020) *Antioxidants*, 9.  
32707949
- Kalyn, M., Ekker, M.  
**Cerebroventricular Microinjections of MPTP on adult zebrafish induces dopaminergic neuronal death, mitochondrial fragmentation, and sensorimotor impairments**  
(2021) *Front. Neurosci*, 15, p. 718244.  
34512252
- Risiglione, P., Leggio, L., Cubisino, S.A., Reina, S., Paternò, G., Marchetti, B., Magrì, A., Messina, A.  
**High-resolution respirometry reveals MPP+ Mitochondrial toxicity mechanism in a cellular model of Parkinson's Disease**  
(2020) *Int. J. Mol. Sci*, 21.
- Anichtchik, O.V., Kaslin, J., Peitsaro, N., Scheinin, M., Panula, P.  
**Neurochemical and behavioural changes in zebrafish *Danio rerio* after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine**  
(2004) *J. Neurochem*, 88, pp. 443-453.  
14690532
- Sarath Babu, N., Murthy, C.L.N., Kakara, S., Sharma, R., Brahmendra Swamy, C.V., Idris, M.M.  
**1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine induced Parkinson's disease in zebrafish**  
(2016) *Proteomics*, 16, pp. 1407-1420.  
26959078
- Selvaraj, V., Venkatasubramanian, H., Ilango, K., Santhakumar, K.  
**A simple method to study motor and non-motor behaviors in adult zebrafish**  
(2019) *J. Neurosci. Methods*, 320, pp. 16-25.  
30871986
- Razali, K., Mohd Nasir, M.H., Othman, N., Doolaanea, A.A., Kumar, J., Nabeel Ibrahim, W., Mohamed, W.M.

- Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study**  
(2022) *PLoS ONE*, 17.
- Hu, P., Liu, M., Zhang, D., Wang, J., Niu, H., Liu, Y., Wu, Z., Shen, Y.  
**Global identification of the genetic networks and cis-regulatory elements of the cold response in zebrafish**  
(2015) *Nucleic Acids Res*, 43, pp. 9198-9213.
  - Kim, Y.-C., Lee, S.-R., Jeon, H.-J., Kim, K., Kim, M.-J., Choi, S.-D., Lee, S.-E.  
**Acute toxicities of fluorene, fluorene-1-carboxylic acid, and fluorene-9-carboxylic acid on zebrafish embryos (Danio rerio): Molecular mechanisms of developmental toxicities of fluorene-1-carboxylic acid**  
(2020) *Chemosphere*, 260, p. 127622.
  - Chang, K.-H., Chen, C.-M.  
**The role of oxidative stress in Parkinson's disease**  
(2020) *Antioxidants*, 9.
  - Li, J.-L., Lin, T.-Y., Chen, P.-L., Guo, T.-N., Huang, S.-Y., Chen, C.-H., Lin, C.-H., Chan, C.-C.  
**Mitochondrial function and Parkinson's disease: From the perspective of the electron transport chain**  
(2021) *Front. Mol. Neurosci*, 14, p. 315.
  - Killackey, S.A., Philpott, D.J., Girardin, S.E.  
**Mitophagy pathways in health and disease**  
(2020) *J. Cell Biol*, 219, p. e202004029.  
32926082
  - Yang, H., Wang, H., Andersson, U.  
**Targeting inflammation driven by HMGB1**  
(2020) *Front. Immunol*, 11, p. 484.  
32265930
  - Yang, H., Wang, H., Ju, Z., Ragab, A.A., Lundbäck, P., Long, W., Valdes-Ferrer, S.I., Li, J.  
**MD-2 is required for disulfide HMGB1-dependent TLR4 signaling**  
(2015) *J. Exp. Med*, 212, pp. 5-14.  
25559892
  - Troncoso-Escudero, P., Parra, A., Nassif, M., Vidal, R.L.  
**Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease**  
(2018) *Front. Neurol*, 9, p. 860.  
30459700
  - Grotemeyer, A., McFleder, R.L., Wu, J., Wischhusen, J., Ip, C.W.  
**Neuroinflammation in Parkinson's Disease—Putative Pathomechanisms and Targets for Disease-Modification**  
(2022) *Front. Immunol*, 13, p. 2301.
  - Castillo-Rangel, C., Marin, G., Hernández-Contreras, K.A., Vichi-Ramírez, M.M., Zarate-Calderon, C., Torres-Pineda, O., Diaz-Chiguer, D.L., Tecu-Cortes, J.A.  
**Neuroinflammation in Parkinson's Disease: From Gene to Clinic: A Systematic Review**  
(2023) *Int. J. Mol. Sci*, 24.
  - Wang, K., Huang, J., Xie, W., Huang, L., Zhong, C., Chen, Z.  
**Beclin1 and HMGB1 ameliorate the  $\alpha$ -synuclein-mediated autophagy inhibition in PC12 cells**  
(2016) *Diagn. Pathol*, 11, p. 15.

- Angelopoulou, E., Piperi, C., Papavassiliou, A.G.  
**High-mobility group box 1 in Parkinson's disease: From pathogenesis to therapeutic approaches**  
(2018) *J. Neurochem*, 146, pp. 211-218.
- Yang, Y., Han, C., Guo, L., Guan, Q.  
**High expression of the HMGB1–TLR4 axis and its downstream signaling factors in patients with Parkinson's disease and the relationship of pathological staging**  
(2018) *Brain Behav*, 8, p. e00948.
- Huebener, P., Gwak, G.-Y., Pradere, J.-P., Quinzii, C.M., Friedman, R., Lin, C.-S., Trent, C.M., Dapito, D.H.  
**High-mobility group box 1 is dispensable for autophagy, mitochondrial quality control, and organ function in vivo**  
(2014) *Cell Metab*, 19, pp. 539-547.
- Adebayo, M., Singh, S., Singh, A.P., Dasgupta, S.  
**Mitochondrial fusion and fission: The fine-tune balance for cellular homeostasis**  
(2021) *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol*, 35, p. e21620.
- Ding, W.-X., Yin, X.-M.  
**Mitophagy: Mechanisms, pathophysiological roles, and analysis**  
(2012) *Biol. Chem*, 393, pp. 547-564.
- Lee, T.T., Chen, P.L., Su, M.P., Li, J.C., Chang, Y.W., Liu, R.W., Juan, H.F., Tsai, Y.C.  
**Loss of Fis1 impairs proteostasis during skeletal muscle aging in Drosophila**  
(2021) *Aging Cell*, 20, p. e13379.  
34061429
- Scaini, G., Mason, B.L., Diaz, A.P., Jha, M.K., Soares, J.C., Trivedi, M.H., Quevedo, J.  
**Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?**  
(2022) *Mol. Psychiatry*, 27, pp. 1095-1102.  
34650203
- Bhatti, J.S., Bhatti, G.K., Reddy, P.H.  
**Mitochondrial dysfunction and oxidative stress in metabolic disorders—A step towards mitochondria based therapeutic strategies**  
(2017) *Biochim. Biophys. Acta BBA—Mol. Basis Dis*, 1863, pp. 1066-1077.  
27836629
- Geto, Z., Molla, M.D., Challa, F., Belay, Y., Getahun, T.  
**Mitochondrial dynamic dysfunction as a main triggering factor for inflammation associated chronic non-communicable diseases**  
(2020) *J. Inflamm. Res*, 13, pp. 97-107.
- Truban, D., Hou, X., Caulfield, T.R., Fiesel, F.C., Springer, W.  
**PINK1, Parkin, and mitochondrial quality control: What can we learn about Parkinson's disease pathobiology?**  
(2017) *J. Park. Dis*, 7, pp. 13-29.  
27911343
- Moura, K.C.V., Campos Junior, M., de Rosso, A.L.Z., Nicaretta, D.H., Pereira, J.S., Silva, D.J., dos Santos, F.L., Pimentel, M.M.G.  
**Genetic analysis of PARK2 and PINK1 genes in Brazilian patients with early-onset Parkinson's disease**  
(2013) *Dis. Mrk*, 35, pp. 181-185.
- Puschmann, A., Fiesel, F.C., Caulfield, T.R., Hudec, R., Ando, M., Truban, D., Hou, X., James, E.D.

- Heterozygous PINK1 p. G411S increases risk of Parkinson's disease via a dominant-negative mechanism**  
(2017) *Brain*, 140, pp. 98-117.
- Quinn, P.M., Moreira, P.I., Ambrósio, A.F., Alves, C.H.  
**PINK1/PARKIN signalling in neurodegeneration and neuroinflammation**  
(2020) *Acta Neuropathol. Commun*, 8, p. 189.
  - Narendra, D.P., Jin, S.M., Tanaka, A., Suen, D.-F., Gautier, C.A., Shen, J., Cookson, M.R., Youle, R.J.  
**PINK1 is selectively stabilized on impaired mitochondria to activate Parkin**  
(2010) *PLoS Biol*, 8, 20126261
  - Selvaraj, S., Piramanayagam, S.  
**Impact of gene mutation in the development of Parkinson's disease**  
(2019) *Genes Dis*, 6, pp. 120-128. 31193965
  - Subramaniam, S.R., Chesselet, M.-F.  
**Mitochondrial dysfunction and oxidative stress in Parkinson's disease**  
(2013) *Prog. Neurobiol*, 106, pp. 17-32. 23643800
  - Grünewald, A., Kumar, K.R., Sue, C.M.  
**New insights into the complex role of mitochondria in Parkinson's disease**  
(2019) *Prog. Neurobiol*, 177, pp. 73-93.
  - Santoro, M., Maetzler, W., Stathakos, P., Martin, H.L., Hobert, M.A., Rattay, T.W., Gasser, T., Tracey, K.J.  
**In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin**  
(2016) *Neurobiol. Dis*, 91, pp. 59-68.
  - Ren, Q., Jiang, X., Paudel, Y.N., Gao, X., Gao, D., Zhang, P., Sheng, W., Zhang, X.  
**Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson's disease like pathology in Zebrafish**  
(2022) *J. Ethnopharmacol*, 292, p. 115234.
  - Paudel, Y.N., Angelopoulou, E., Piperi, C., Othman, I., Shaikh, M.F.  
**HMGB1-mediated neuroinflammatory responses in brain injuries: Potential mechanisms and therapeutic opportunities**  
(2020) *Int. J. Mol. Sci*, 21.
  - Mo, J., Hu, J., Cheng, X.  
**The role of high mobility group box 1 in neuroinflammatory related diseases**  
(2023) *Biomed. Pharmacother*, 161, p. 114541.
  - Zhang, S., Hu, L., Jiang, J., Li, H., Wu, Q., Ooi, K., Wang, J., Xia, C.  
**HMGB1/RAGE axis mediates stress-induced RVLM neuroinflammation in mice via impairing mitophagy flux in microglia**  
(2020) *J. Neuroinflamm*, 17, p. 15.
  - Gorecki, A.M., Anyaegbu, C.C., Anderton, R.S.  
**TLR2 and TLR4 in Parkinson's disease pathogenesis: The environment takes a toll on the gut**  
(2021) *Transl. Neurodegener*, 10, p. 47.
  - Kouli, A., Torsney, K.M., Kuan, W.-L.  
(2018) *Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis*, pp. 3-26.

Exon Publications, Brisbane, Australia

- Sallinen, V., Torkko, V., Sundvik, M., Reenilä, I., Khrustalyov, D., Kaslin, J., Panula, P.  
**MPTP and MPP+ target specific aminergic cell populations in larval zebrafish**  
(2009) *J. Neurochem*, 108, pp. 719-731.  
19046410
- Goloborshcheva, V.V., Kucheryanu, V.G., Voronina, N.A., Teterina, E.V., Ustyugov, A.A.,  
Morozov, S.G.  
**Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta  
Dopaminergic Neurons**  
(2022) *Biomedicines*, 10.  
36140378
- DeMaagd, G., Philip, A.  
**Parkinson's disease and its management: Part 1: Disease entity, risk factors,  
pathophysiology, clinical presentation, and diagnosis**  
(2015) *Pharm. Ther.*, 40, p. 504.
- Surmeier, D.J.  
**Determinants of dopaminergic neuron loss in Parkinson's disease**  
(2018) *FEBS J*, 285, pp. 3657-3668.  
30028088

**Correspondence Address**

Mohamed W.M.Y.; Department of Basic Medical Sciences, Pahang, Malaysia; email: wmy107@gmail.com

**Publisher:** Multidisciplinary Digital Publishing Institute (MDPI)

**ISSN:** 20763425

**Language of Original Document:** English

**Abbreviated Source Title:** Brain Sci.

2-s2.0-85166329608

**Document Type:** Article

**Publication Stage:** Final

**Source:** Scopus

**ELSEVIER**

Copyright © 2024 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

 RELX Group™